David A. Siegel I Mab Call Options Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
41Shares Held
15.8MCall Options Held
3KPut Options Held
1.9K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$7.39 Million0.3% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$4.46 Million3.04% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.38MShares$1.48 Million0.07% of portfolio
-
Two Sigma Investments, LP New York, NY478KShares$511,9320.0% of portfolio
-
International Biotechnology Trust PLC London, X0310KShares$332,2330.14% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $88.9M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...